Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (27 February 2026 - 26 March 2026)

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (30 January 2026 - 26 February 2026)

Questions and answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies

Questions and answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies - tracked changes

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 12, Status: Authorised

Highlights from the third expert panels and notified bodies workshop

Human medicines European public assessment report (EPAR): Usrenty, ustekinumab, Date of authorisation: 17/09/2025, Revision: 2, Status: Authorised

Highlights from the second expert panels and notified bodies workshop

Annex to agenda of the CHMP meeting 18-21 May 2026

Agenda of the CHMP meeting 18-21 May 2026